Published in Mol Pharmacol on July 01, 1992
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. J Med Chem (1992) 2.01
Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor. J Biol Chem (1995) 1.92
Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol (2007) 1.58
Modelling the P2Y purinoceptor using rhodopsin as template. Drug Des Discov (1995) 1.35
Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition. Mol Pharmacol (1996) 1.33
Molecular modeling of adenosine receptors. I. The ligand binding site on the A1 receptor. Drug Des Discov (1992) 1.25
Covalent binding of a selective agonist irreversibly activates guinea pig coronary artery A2 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol (1993) 0.94
Application of the functionalized congener approach to dendrimer-based signaling agents acting through A(2A) adenosine receptors. Purinergic Signal (2008) 0.87
High affinity acylating antagonists for muscarinic receptors. Life Sci (1992) 0.82
"Cleavable trifunctional" approach to receptor affinity labeling: chemical regeneration of binding to A1-adenosine receptors. Bioconjug Chem (1995) 0.82
Solubilized rabbit striatal A2a-adenosine receptors: stability and antagonist binding. Arch Biochem Biophys (1993) 0.81
Molecular Characterization of A(1) and A(2a) Adenosine Receptors. Drug Dev Res (1993) 0.81
8-(3-Isothiocyanatostyryl)caffeine Is a Selective, Irreversible Inhibitor of Striatal A(2)-Adenosine Receptors. Drug Dev Res (1993) 0.78
Molecular probes for muscarinic receptors: functionalized congeners of selective muscarinic antagonists. Life Sci (1995) 0.77
Structure-Based Design of Reactive Nucleosides for Site-Specific Modification of the A2A Adenosine Receptor. ACS Med Chem Lett (2014) 0.76
Selective amplification and cloning of four new members of the G protein-coupled receptor family. Science (1989) 6.67
Modification of histidyl residues in proteins by diethylpyrocarbonate. Methods Enzymol (1977) 4.25
[3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther (1989) 4.18
Cardiovascular purinoceptors. Physiol Rev (1990) 3.70
The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. J Clin Invest (1990) 2.12
RDC8 codes for an adenosine A2 receptor with physiological constitutive activity. Biochem Biophys Res Commun (1990) 1.94
Adenosine A1 and A2 receptors: structure--function relationships. Med Res Rev (1992) 1.62
A2A adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: characterization with radioligand binding and by activation of adenylate cyclase. Mol Pharmacol (1992) 1.57
Probing the adenosine receptor with adenosine and xanthine biotin conjugates. FEBS Lett (1985) 1.52
Cloning and expression of an A1 adenosine receptor from rat brain. Mol Pharmacol (1991) 1.51
Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. Proc Natl Acad Sci U S A (1989) 1.50
Agonist derived molecular probes for A2 adenosine receptors. J Mol Recognit (1989) 1.43
Distinct pathways of desensitization of A1- and A2-adenosine receptors in DDT1 MF-2 cells. Mol Pharmacol (1991) 1.42
The A2 adenosine receptor: guanine nucleotide modulation of agonist binding is enhanced by proteolysis. Mol Pharmacol (1991) 1.32
Behavioral effects of A1- and A2-selective adenosine agonists and antagonists: evidence for synergism and antagonism. J Pharmacol Exp Ther (1991) 1.31
High affinity acylating antagonists for the A1 adenosine receptor: identification of binding subunit. Mol Pharmacol (1988) 1.17
Electrophilic derivatives of purines as irreversible inhibitors of A1 adenosine receptors. J Med Chem (1989) 1.13
Separation of solubilized A2 adenosine receptors of human platelets from non-receptor [3H]NECA binding sites by gel filtration. Naunyn Schmiedebergs Arch Pharmacol (1988) 1.06
Trifunctional agents as a design strategy for tailoring ligand properties: irreversible inhibitors of A1 adenosine receptors. Bioconjug Chem (1991) 0.97
Chemical modification of A1 adenosine receptors in rat brain membranes. Evidence for histidine in different domains of the ligand binding site. J Biol Chem (1988) 0.95
[(3)H]XAC (xanthine amine congener) is a radioligand for A(2)-adenosine receptors in rabbit striatum. Neurochem Int (1991) 0.85
Chemical modification of adenosine A1 receptors. Implications for the interaction with R-PIA, DPCPX and amiloride. Biochem Pharmacol (1990) 0.84
Evidence for the participation of histidine residues located in the 56 kDa C-terminal polypeptide domain of ADP-ribosyl transferase in its catalytic activity. FEBS Lett (1990) 0.81
Inhibition of muscarinic cholinergic receptors by disulfide reducing agents and arsenicals. Differential effect on locust and rat. Biochem Pharmacol (1991) 0.78
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A (1994) 5.44
The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem (1997) 4.03
Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc Natl Acad Sci U S A (1992) 3.91
The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem (1993) 2.66
125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor. Mol Pharmacol (1994) 2.65
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists. J Med Chem (1994) 2.47
Beta-adrenergic receptors: biochemical mechanisms of physiological regulation. Physiol Rev (1984) 2.38
Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol (1995) 2.19
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. J Med Chem (1994) 2.10
Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A (1996) 2.02
A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol Pharmacol (1994) 1.87
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology (1997) 1.86
Adenosine A1 and A2 receptors: structure--function relationships. Med Res Rev (1992) 1.62
The A1 adenosine receptor. Identification of the binding subunit by photoaffinity cross-linking. J Biol Chem (1985) 1.52
A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett (1993) 1.51
Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. Proc Natl Acad Sci U S A (1989) 1.50
Heterologous desensitization of the inhibitory A1 adenosine receptor-adenylate cyclase system in rat adipocytes. Regulation of both Ns and Ni. J Biol Chem (1987) 1.50
The role of receptor structure in determining adenosine receptor activity. Pharmacol Ther (2000) 1.43
Agonist derived molecular probes for A2 adenosine receptors. J Mol Recognit (1989) 1.43
Distinct pathways of desensitization of A1- and A2-adenosine receptors in DDT1 MF-2 cells. Mol Pharmacol (1991) 1.42
A new high affinity, iodinated adenosine receptor antagonist as a radioligand/photoaffinity crosslinking probe. Mol Pharmacol (1987) 1.42
Mechanisms of membrane-receptor regulation. Biochemical, physiological, and clinical insights derived from studies of the adrenergic receptors. N Engl J Med (1984) 1.35
Cloning, expression, and characterization of the unique bovine A1 adenosine receptor. Studies on the ligand binding site by site-directed mutagenesis. J Biol Chem (1992) 1.32
Human cardiac beta-adrenergic receptors: subtype heterogeneity delineated by direct radioligand binding. Life Sci (1983) 1.32
The A2 adenosine receptor: guanine nucleotide modulation of agonist binding is enhanced by proteolysis. Mol Pharmacol (1991) 1.32
Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem (1998) 1.32
Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. J Med Chem (1996) 1.31
Differential interaction with and regulation of multiple G-proteins by the rat A3 adenosine receptor. J Biol Chem (1995) 1.26
Ring-Constrained (N)-methanocarba nucleosides as adenosine receptor agonists: independent 5'-uronamide and 2'-deoxy modifications. Bioorg Med Chem Lett (2001) 1.26
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors. J Med Chem (1995) 1.26
Adenosine receptors. Neuropharmacology (1995) 1.24
Characterization of the A1 adenosine receptor-adenylate cyclase system of cerebral cortex using an agonist photoaffinity ligand. J Neurochem (1986) 1.21
Mammalian beta-adrenergic receptors. Structural differences in beta 1 and beta 2 subtypes revealed by peptide maps. J Biol Chem (1983) 1.21
Photoaffinity cross-linked A1 adenosine receptor-binding subunits. Homologous glycoprotein expression by different tissues. J Biol Chem (1986) 1.20
The A1 adenosine receptor. Solubilization and characterization of a guanine nucleotide-sensitive form of the receptor. J Biol Chem (1985) 1.18
Isobutylmethylxanthine stimulates adenylate cyclase by blocking the inhibitory regulatory protein, Gi. Mol Pharmacol (1988) 1.17
Role of the second extracellular loop of adenosine receptors in agonist and antagonist binding. Analysis of chimeric A1/A3 adenosine receptors. J Biol Chem (1994) 1.16
Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem (1996) 1.13
125I-4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor. Mol Pharmacol (1995) 1.13
Electrophilic derivatives of purines as irreversible inhibitors of A1 adenosine receptors. J Med Chem (1989) 1.13
Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia. Eur J Pharmacol (1994) 1.11
Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists. J Med Chem (1997) 1.09
Photoaffinity labelling of mammalian beta-adrenergic receptors: metal-dependent proteolysis explains apparent heterogeneity. Biochem Biophys Res Commun (1983) 1.09
A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci U S A (2000) 1.09
Demonstration of distinct agonist and antagonist conformations of the A1 adenosine receptor. J Biol Chem (1989) 1.09
Adenosine receptors: clinical implications and biochemical mechanisms. Prog Drug Res (1988) 1.08
Reciprocal modulation of agonist and antagonist binding to A1 adenosine receptors by guanine nucleotides is mediated via a pertussis toxin-sensitive G protein. J Pharmacol Exp Ther (1988) 1.08
Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem (1999) 1.07
Demonstration of both A1 and A2 adenosine receptors in DDT1 MF-2 smooth muscle cells. Mol Pharmacol (1990) 1.07
Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors. J Med Chem (1995) 1.06
6-phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem (1996) 1.06
The utilization of a unified pharmacophore query in the discovery of new antagonists of the adenosine receptor family. Bioorg Med Chem Lett (2000) 1.06
Oxidative stress increases A1 adenosine receptor expression by activating nuclear factor kappa B. Mol Pharmacol (1998) 1.05
Selective ligands for rat A3 adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine 7-riboside derivatives. J Med Chem (1994) 1.05
Clinical relevance of exercise-induced S-T segment elevation. Am J Cardiol (1980) 1.04
Chronic caffeine ingestion sensitizes the A1 adenosine receptor-adenylate cyclase system in rat cerebral cortex. J Clin Invest (1986) 1.02
Mammalian beta-adrenergic receptors. Distinct glycoprotein populations containing high mannose or complex type carbohydrate chains. J Biol Chem (1984) 1.01
Differential expression of peroxiredoxin subtypes in human brain cell types. J Neurosci Res (1999) 1.01
Chronic adenosine A1 receptor agonist and antagonist: effect on receptor density and N-methyl-D-aspartate induced seizures in mice. Eur J Pharmacol (1994) 0.99
The cardiac beta-adrenergic receptor. Structural similarities of beta 1 and beta 2 receptor subtypes demonstrated by photoaffinity labeling. J Biol Chem (1983) 0.98
Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors. J Med Chem (1996) 0.98
Purification and characterization of bovine cerebral cortex A1 adenosine receptor. Arch Biochem Biophys (1990) 0.98
Multiple components of the A1 adenosine receptor-adenylate cyclase system are regulated in rat cerebral cortex by chronic caffeine ingestion. J Clin Invest (1988) 0.97
Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists. J Med Chem (1992) 0.97
Adenosine receptors. Annu Rev Physiol (1992) 0.97
Trifunctional agents as a design strategy for tailoring ligand properties: irreversible inhibitors of A1 adenosine receptors. Bioconjug Chem (1991) 0.97
Hormone-sensitive adenylate cyclase. Delineation of a trypsin-sensitive site in the pathway of receptor-mediated inhibition. J Biol Chem (1982) 0.96
Characterization of human striatal A2-adenosine receptors using radioligand binding and photoaffinity labeling. J Recept Res (1992) 0.96
Adenosine receptor prodrugs: synthesis and biological activity of derivatives of potent, A1-selective agonists. J Pharm Sci (1994) 0.96
Molecular basis for subtype-specific desensitization of inhibitory adenosine receptors. Analysis of a chimeric A1-A3 adenosine receptor. J Biol Chem (1996) 0.93
Glycoprotein nature of the A2-adenosine receptor binding subunit. Mol Pharmacol (1990) 0.93
A novel site of action of a high affinity A1 adenosine receptor antagonist. Biochem Biophys Res Commun (1988) 0.92
Hypothyroidism modulates beta adrenergic receptor adenylate cyclase interactions in rat reticulocytes. J Clin Invest (1981) 0.91
Solubilization and characterization of the A2-adenosine receptor. J Recept Res (1993) 0.91
Characterization of the human A1 adenosine receptor gene. Evidence for alternative splicing. J Biol Chem (1994) 0.90
Posttranscriptional mRNA processing as a mechanism for regulation of human A1 adenosine receptor expression. Proc Natl Acad Sci U S A (1994) 0.89
Affinity chromatography of the bovine cerebral cortex A1 adenosine receptor. FEBS Lett (1989) 0.89
Translocation and uncoupling of the beta-adrenergic receptor in rat lung after catecholamine promoted desensitization in vivo. Endocrinology (1984) 0.89
Effect of pertussis toxin on alpha 2-adrenoceptors: decreased formation of the high-affinity state for agonists. FEBS Lett (1984) 0.89
Identification of an adenosine receptor domain specifically involved in binding of 5'-substituted adenosine agonists. J Biol Chem (1994) 0.89
Induction of multiple effects on adenylyl cyclase regulation by chronic activation of the human A3 adenosine receptor. Mol Pharmacol (1997) 0.89
Deglycosylated mammalian beta 2-adrenergic receptors: effect on radioligand binding and peptide mapping. Arch Biochem Biophys (1985) 0.89
The new cardiotonic agent sulmazole is an A1 adenosine receptor antagonist and functionally blocks the inhibitory regulator, Gi. Mol Pharmacol (1988) 0.88
Agonist-dependent phosphorylation and desensitization of the rat A3 adenosine receptor. Evidence for a G-protein-coupled receptor kinase-mediated mechanism. J Biol Chem (1995) 0.88
Identification of an A2a adenosine receptor domain specifically responsible for mediating short-term desensitization. Biochemistry (1997) 0.88
Identification of threonine residues controlling the agonist-dependent phosphorylation and desensitization of the rat A(3) adenosine receptor. Mol Pharmacol (2000) 0.87
Bacterial endocarditis with aortic regurgitation: implications of embolism. South Med J (1980) 0.87
Functional consequences of A1 adenosine-receptor phosphorylation by the beta-adrenergic receptor kinase. Biochim Biophys Acta (1993) 0.86
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors. J Med Chem (1994) 0.86